Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077219 | 1.00 | EGFR (0.42) | EGFRSRCGAAGFERHPGD | |
| SCHEMBL1076360 | 0.87 | GAA (0.49) | EGFRGAAGFERHPGDLMNA | |
| SCHEMBL1076872 | 0.83 | KDM4E (0.35) | GAAGFERHPGDLMNAHTT | |
| SCHEMBL1076868 | 0.83 | KDM4E (0.35) | GAAGFERHPGDLMNAHTT | |
| SCHEMBL30385406 | 0.80 | AGTR1 (0.46) | EGFRSRCGAAGFERHPGD | |
| SCHEMBL1075323 | 0.80 | AGTR1 (0.46) | EGFRSRCGAAGFERHPGD | |
| SCHEMBL1038398 | 0.79 | EGFR (0.40) | EGFRSRCGAAGFERHPGD | |
| SCHEMBL13460255 | 0.78 | KDM4E (0.41) | GAASMN1; SMN2HDAC6KDM4EL3MBTL1 | |
| SCHEMBL1076870 | 0.78 | KDM4E (0.36) | GAAGFERHPGDLMNAHTT | |
| SCHEMBL1077236 | 0.78 | EGFR (0.42) | EGFRSRCGAAGFERHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | EGFR 98/4885SRC 3222/4885GAA 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.